Loading…
Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex
Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compressi...
Saved in:
Published in: | Pharmaceutical development and technology 2004, Vol.9 (2), p.155-162 |
---|---|
Main Authors: | , , , |
Format: | Article |
Language: | English |
Subjects: | |
Citations: | Items that this one cites Items that cite this one |
Online Access: | Get full text |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
cited_by | cdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03 |
---|---|
cites | cdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03 |
container_end_page | 162 |
container_issue | 2 |
container_start_page | 155 |
container_title | Pharmaceutical development and technology |
container_volume | 9 |
creator | Bonferoni, M. C. Rossi, S. Ferrari, F. Caramella, C. |
description | Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion. |
doi_str_mv | 10.1081/PDT-120027428 |
format | article |
fullrecord | <record><control><sourceid>proquest_infor</sourceid><recordid>TN_cdi_informahealthcare_journals_10_1081_PDT_120027428</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>66639863</sourcerecordid><originalsourceid>FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</originalsourceid><addsrcrecordid>eNp1kMtv1DAQhyNERR9w5Ip8gVuoH0lsH2GXAlKlVmg5WxNnTFM59mInQPnr69Uujx568kj-5jczX1W9ZPQto4qdX683NeOUctlw9aQ6YVTLWqtOPt3VStSyaelxdZrzLaVMado-q45ZyylvZXNSwRp_oI_bCcNMoiNXCTxZxTCn6D0O5At6hIxkA73HmVzENC0e5jGGTN6Xj4HEQNajn0f4jVO9gpTgG2KAUFKmrcdfz6sjBz7ji8N7Vn29-LBZfaovrz5-Xr27rK1o1FwzOXDWd0qztreaaqZ3JzUguOyY6pmwjeZMOM06oJZ3qB3XvXBoXYMNUnFWvdnnblP8vmCezTRmi95DwLhk03WdKF5EAes9aFPMOaEz2zROkO4Mo2bn1BSn5q_Twr86BC_9hMM_-iCxAK8PAGQL3iUIdsz_cVLqTu0Gqz03Blc8ws-Y_GBmuPMx_WkSj-0gH7TeIPj5xkJCcxuXFIrYR7a_B35Hor8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>66639863</pqid></control><display><type>article</type><title>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</title><source>EBSCOhost Business Source Ultimate</source><source>Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list)</source><creator>Bonferoni, M. C. ; Rossi, S. ; Ferrari, F. ; Caramella, C.</creator><creatorcontrib>Bonferoni, M. C. ; Rossi, S. ; Ferrari, F. ; Caramella, C.</creatorcontrib><description>Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion.</description><identifier>ISSN: 1083-7450</identifier><identifier>EISSN: 1097-9867</identifier><identifier>DOI: 10.1081/PDT-120027428</identifier><identifier>PMID: 15202574</identifier><language>eng</language><publisher>New York, NY: Informa UK Ltd</publisher><subject>Administration, Oral ; Biological and medical sciences ; Carrageenan - chemistry ; Compressive Strength ; Controlled release ; Delayed-Action Preparations ; Diltiazem - administration & dosage ; Diltiazem - chemistry ; Diltiazem HCl ; Drug Compounding - methods ; Drug-polymer complex ; Excipients - chemistry ; General pharmacology ; Hydrogen-Ion Concentration ; Lambda carrageenan ; Medical sciences ; Pharmaceutical technology. Pharmaceutical industry ; Pharmacology. Drug treatments ; Solubility ; Tablets ; Time Factors</subject><ispartof>Pharmaceutical development and technology, 2004, Vol.9 (2), p.155-162</ispartof><rights>2004 Informa UK Ltd All rights reserved: reproduction in whole or part not permitted 2004</rights><rights>2004 INIST-CNRS</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</citedby><cites>FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,4024,27923,27924,27925</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=15779683$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/15202574$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bonferoni, M. C.</creatorcontrib><creatorcontrib>Rossi, S.</creatorcontrib><creatorcontrib>Ferrari, F.</creatorcontrib><creatorcontrib>Caramella, C.</creatorcontrib><title>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</title><title>Pharmaceutical development and technology</title><addtitle>Pharm Dev Technol</addtitle><description>Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion.</description><subject>Administration, Oral</subject><subject>Biological and medical sciences</subject><subject>Carrageenan - chemistry</subject><subject>Compressive Strength</subject><subject>Controlled release</subject><subject>Delayed-Action Preparations</subject><subject>Diltiazem - administration & dosage</subject><subject>Diltiazem - chemistry</subject><subject>Diltiazem HCl</subject><subject>Drug Compounding - methods</subject><subject>Drug-polymer complex</subject><subject>Excipients - chemistry</subject><subject>General pharmacology</subject><subject>Hydrogen-Ion Concentration</subject><subject>Lambda carrageenan</subject><subject>Medical sciences</subject><subject>Pharmaceutical technology. Pharmaceutical industry</subject><subject>Pharmacology. Drug treatments</subject><subject>Solubility</subject><subject>Tablets</subject><subject>Time Factors</subject><issn>1083-7450</issn><issn>1097-9867</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2004</creationdate><recordtype>article</recordtype><recordid>eNp1kMtv1DAQhyNERR9w5Ip8gVuoH0lsH2GXAlKlVmg5WxNnTFM59mInQPnr69Uujx568kj-5jczX1W9ZPQto4qdX683NeOUctlw9aQ6YVTLWqtOPt3VStSyaelxdZrzLaVMado-q45ZyylvZXNSwRp_oI_bCcNMoiNXCTxZxTCn6D0O5At6hIxkA73HmVzENC0e5jGGTN6Xj4HEQNajn0f4jVO9gpTgG2KAUFKmrcdfz6sjBz7ji8N7Vn29-LBZfaovrz5-Xr27rK1o1FwzOXDWd0qztreaaqZ3JzUguOyY6pmwjeZMOM06oJZ3qB3XvXBoXYMNUnFWvdnnblP8vmCezTRmi95DwLhk03WdKF5EAes9aFPMOaEz2zROkO4Mo2bn1BSn5q_Twr86BC_9hMM_-iCxAK8PAGQL3iUIdsz_cVLqTu0Gqz03Blc8ws-Y_GBmuPMx_WkSj-0gH7TeIPj5xkJCcxuXFIrYR7a_B35Hor8</recordid><startdate>2004</startdate><enddate>2004</enddate><creator>Bonferoni, M. C.</creator><creator>Rossi, S.</creator><creator>Ferrari, F.</creator><creator>Caramella, C.</creator><general>Informa UK Ltd</general><general>Taylor & Francis</general><general>Informa Healthcare</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>2004</creationdate><title>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</title><author>Bonferoni, M. C. ; Rossi, S. ; Ferrari, F. ; Caramella, C.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2004</creationdate><topic>Administration, Oral</topic><topic>Biological and medical sciences</topic><topic>Carrageenan - chemistry</topic><topic>Compressive Strength</topic><topic>Controlled release</topic><topic>Delayed-Action Preparations</topic><topic>Diltiazem - administration & dosage</topic><topic>Diltiazem - chemistry</topic><topic>Diltiazem HCl</topic><topic>Drug Compounding - methods</topic><topic>Drug-polymer complex</topic><topic>Excipients - chemistry</topic><topic>General pharmacology</topic><topic>Hydrogen-Ion Concentration</topic><topic>Lambda carrageenan</topic><topic>Medical sciences</topic><topic>Pharmaceutical technology. Pharmaceutical industry</topic><topic>Pharmacology. Drug treatments</topic><topic>Solubility</topic><topic>Tablets</topic><topic>Time Factors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bonferoni, M. C.</creatorcontrib><creatorcontrib>Rossi, S.</creatorcontrib><creatorcontrib>Ferrari, F.</creatorcontrib><creatorcontrib>Caramella, C.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Pharmaceutical development and technology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bonferoni, M. C.</au><au>Rossi, S.</au><au>Ferrari, F.</au><au>Caramella, C.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex</atitle><jtitle>Pharmaceutical development and technology</jtitle><addtitle>Pharm Dev Technol</addtitle><date>2004</date><risdate>2004</risdate><volume>9</volume><issue>2</issue><spage>155</spage><epage>162</epage><pages>155-162</pages><issn>1083-7450</issn><eissn>1097-9867</eissn><abstract>Diltiazem HCl and lambda carrageenan react in distilled water to give a slightly soluble interaction product. The aim of this work was to verify the possible employment of lambda carrageenan-diltiazem (DTZ) complex in controlled-release formulations. The influence of complex particle size, compression force, pH of the dissolution medium, and tablet dimensions on drug release has been evaluated. The results confirm the suitability of the DTZ-carrageenan interaction product for controlled-release formulations. Good compaction properties allow tablets to slowly erode, with only the addition of the amount of hydroxypropyl methylcellulose (HPMC) necessary as a binding agent. The use of the finest sieve fraction results in the highest crushing strength values and in the slowest release rate, both in pH 1.2 and in pH 6.8. The force of compression does not affect the drug release for values over 16 kN. The release rate increases when the geometry of the tablet is varied so the surface volume ratio of the tablet is increased, suggesting a release mechanism involving surface dissolution erosion.</abstract><cop>New York, NY</cop><pub>Informa UK Ltd</pub><pmid>15202574</pmid><doi>10.1081/PDT-120027428</doi><tpages>8</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1083-7450 |
ispartof | Pharmaceutical development and technology, 2004, Vol.9 (2), p.155-162 |
issn | 1083-7450 1097-9867 |
language | eng |
recordid | cdi_informahealthcare_journals_10_1081_PDT_120027428 |
source | EBSCOhost Business Source Ultimate; Taylor and Francis:Jisc Collections:Taylor and Francis Read and Publish Agreement 2024-2025:Medical Collection (Reading list) |
subjects | Administration, Oral Biological and medical sciences Carrageenan - chemistry Compressive Strength Controlled release Delayed-Action Preparations Diltiazem - administration & dosage Diltiazem - chemistry Diltiazem HCl Drug Compounding - methods Drug-polymer complex Excipients - chemistry General pharmacology Hydrogen-Ion Concentration Lambda carrageenan Medical sciences Pharmaceutical technology. Pharmaceutical industry Pharmacology. Drug treatments Solubility Tablets Time Factors |
title | Development of Oral Controlled Release Tablet Formulations Based on Diltiazem-Carrageenan Complex |
url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T02%3A16%3A19IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_infor&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Development%20of%20Oral%20Controlled%20Release%20Tablet%20Formulations%20Based%20on%20Diltiazem-Carrageenan%20Complex&rft.jtitle=Pharmaceutical%20development%20and%20technology&rft.au=Bonferoni,%20M.%20C.&rft.date=2004&rft.volume=9&rft.issue=2&rft.spage=155&rft.epage=162&rft.pages=155-162&rft.issn=1083-7450&rft.eissn=1097-9867&rft_id=info:doi/10.1081/PDT-120027428&rft_dat=%3Cproquest_infor%3E66639863%3C/proquest_infor%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c348t-17d21b68915bc9091902744a327618b13c49213f916a0c26e9f29b3fecf4e4e03%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=66639863&rft_id=info:pmid/15202574&rfr_iscdi=true |